- Home
- VIGL vs GAN Comparison
VIGL vs GAN Comparison
Compare VIGL & GAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- GAN
- Stock Information
- Founded
- VIGL 2020
- GAN 1999
- Country
- VIGL United States
- GAN United States
- Employees
- VIGL N/A
- GAN N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- GAN Computer Software: Programming Data Processing
- Sector
- VIGL Health Care
- GAN Technology
- Exchange
- VIGL Nasdaq
- GAN Nasdaq
- Market Cap
- VIGL 74.7M
- GAN 81.1M
- IPO Year
- VIGL 2022
- GAN 2020
- Fundamental
- Price
- VIGL $2.41
- GAN $1.79
- Analyst Decision
- VIGL Strong Buy
- GAN
- Analyst Count
- VIGL 5
- GAN 0
- Target Price
- VIGL $16.33
- GAN N/A
- AVG Volume (30 Days)
- VIGL 164.4K
- GAN 85.0K
- Earning Date
- VIGL 05-07-2025
- GAN 05-16-2025
- Dividend Yield
- VIGL N/A
- GAN N/A
- EPS Growth
- VIGL N/A
- GAN N/A
- EPS
- VIGL N/A
- GAN N/A
- Revenue
- VIGL N/A
- GAN $134,998,000.00
- Revenue This Year
- VIGL N/A
- GAN $12.60
- Revenue Next Year
- VIGL N/A
- GAN $5.02
- P/E Ratio
- VIGL N/A
- GAN N/A
- Revenue Growth
- VIGL N/A
- GAN 4.31
- 52 Week Low
- VIGL $1.31
- GAN $1.20
- 52 Week High
- VIGL $6.06
- GAN $1.90
- Technical
- Relative Strength Index (RSI)
- VIGL 60.07
- GAN 55.33
- Support Level
- VIGL $1.75
- GAN $1.78
- Resistance Level
- VIGL $3.00
- GAN $1.82
- Average True Range (ATR)
- VIGL 0.26
- GAN 0.03
- MACD
- VIGL 0.08
- GAN 0.01
- Stochastic Oscillator
- VIGL 55.30
- GAN 70.00
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
About GAN GAN Limited
GAN Ltd provides Software-as-a-Service solutions for online casino gaming and sports betting applications. The company has two operating segments B2B and B2C. The B2B segment develops, markets, and sells instances of GameSTACK, GAN Sports, and iSight Back Office technology that incorporates comprehensive player registration, account funding, and back-office accounting and management tools that enable the casino operators to efficiently, confidently, and effectively extend their presence online in places that have permitted online real money gaming, and The B2C segment, which includes the operations of Coolbet, develops and operates a B2C online sports betting and casino platform that is accessible through its website in markets across Northern Europe, Latin America, and Canada.